Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024
May 22 2024 - 4:05PM
Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical
stage biopharmaceutical company focused on developing novel
therapeutics to address unmet medical needs in liver and viral
diseases, today announced six abstracts have been accepted for
poster presentations, including two Top abstracts, at the European
Association for the Study of the Liver (EASL) Congress 2024, being
held June 5-8 in Milan, Italy. The abstracts released today can be
found on the EASL website at www.easlcongress.eu.
Details from the abstracts released today are as follows:
ALG-000184: Potential best-in-class small molecule CAM-E
for chronic hepatitis B (CHB)
Abstract #: 603
Title: Extended Treatment of HBeAg+ CHB
Subjects with the Capsid Assembly Modulator ALG-000184 with or
without Entecavir is Associated with Reductions in Viral Markers
and Favorable Anti-HBeAb trendsPresenter:
Professor Man-Fung Yuen, MBBS, MD, PhD, DSc, Chair and Chief of the
Division of Gastroenterology and Hepatology, University of Hong
Kong
Abstract #: 895
Title: Dosing with the Capsid Assembly
Modulator ALG-000184 in Untreated HBeAg Negative CHB Subjects
Results in Potent Antiviral Effects Including Suppression of HBV
DNA/RNA and Declines in HBcrAg LevelsPresenter:
Kosh Agarwal, MBBS, MRCP (UK), MD, FRCP (Ed), FRCP (London),
Consultant Hepatologist and Transplant Physician, Institute of
liver Studies, King’s College Hospital NHS Foundation Trust
Abstract #: 2390
Title: Association of baseline characteristics
and plasma ALG-001075 to HBsAg responses in HBeAg+ CHB subjects
following ALG-000184±ETV treatmentPresenter: Kha
Le, PhD
Preclinical
Abstract #: 1298
Title: In vitro and in vivo pharmacological
characterization of human PNPLA3-targeting short interfering RNA
molecules for the treatment of metabolic dysfunction-associated
steatohepatitisPresenter: Jieun Song, PhD
Abstract #: 1338 (Top)
Title: Second generation HBV siRNAs with novel
chemistries demonstrate improved profiles compared with ALG-125755
and other clinical stage siRNAsPresenter: Jin
Hong, PhD
Abstract #: 1763 (Top)
Title: Non-HAP CAM-A ALG-006746 and ALG-006780
induce rapid HBsAg reductions in AAV-HBV mice and have favorable
pharmacokinetic profilesPresenter: Yannick Debing,
PhD
Abstracts identified as “Top” were selected as among the best in
their category. These posters will be displayed during the four
days of the congress.
About Aligos
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical
company that was founded in 2018 with the mission to become a world
leader in the treatment of liver and viral diseases. Aligos’
strategy is to harness the deep expertise and decades of drug
development experience its team has in liver and viral diseases to
discover and develop potentially best-in-class therapeutics for
metabolic dysfunction-associated steatohepatitis (MASH) and viruses
with high unmet medical need such as hepatitis B and
coronaviruses.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this press release that are not historical
facts may be considered “forward-looking statements,” including
without limitation, statements regarding Aligos’ financial results
and performance as well as research and development activities,
including regulatory status and the timing of announcements and
updates relating to our regulatory filings and clinical trials.
Such forward looking statements are subject to substantial risks
and uncertainties that could cause our development programs, future
results, performance, or achievements to differ materially from
those anticipated in the forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
inherent in the drug development process, including Aligos’
clinical-stage of development, the process of designing and
conducting clinical trials, the regulatory approval processes, and
other matters that could affect the sufficiency of Aligos’ capital
resources to fund operations. For a further description of the
risks and uncertainties that could cause actual results to differ
from those anticipated in these forward-looking statements, as well
as risks relating to the business of Aligos in general, see Aligos’
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission on May 7, 2024 and its future periodic reports
to be filed or submitted with the Securities and Exchange
Commission. Except as required by law, Aligos undertakes no
obligation to update any forward-looking statements to reflect new
information, events or circumstances, or to reflect the occurrence
of unanticipated events.
Investor ContactJordyn TaraziVice President,
Investor Relations & Corporate Communications+1 (650)
910-0427jtarazi@aligos.com
Media ContactMichael FitzhughLifeSci
Communicationsmfitzhugh@lifescicomms.com
Aligos Therapeutics (NASDAQ:ALGS)
Historical Stock Chart
From May 2024 to Jun 2024
Aligos Therapeutics (NASDAQ:ALGS)
Historical Stock Chart
From Jun 2023 to Jun 2024